Cediranib ( DrugBank: Cediranib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00326872 (ClinicalTrials.gov) | May 2006 | 16/5/2006 | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas | Neurofibromatosis Type 1;Plexiform Neurofibroma;Spinal Cord Neurofibroma | Drug: Cediranib Maleate | National Cancer Institute (NCI) | NULL | Terminated | 18 Years | N/A | All | 26 | Phase 2 | United States |